Balagula Yevgeniy, Pulitzer Melissa P, Maki Robert G, Myskowski Patricia L
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA.
J Drugs Dermatol. 2011 Sep;10(9):1062-6.
Imatinib mesylate (STI 571; Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) is an orally available tyrosine kinase inhibitor that targets a constitutively activated BCR-ABL tyrosine kinase with additional inhibitory effects on platelet derived growth factor (PDGF) receptors alpha and beta, and KIT. It has revolutionized the treatment of adult and pediatric patients with Philadelphia chromosome positive chronic myelogenous leukemia (CML) and is also FDA-approved for KIT-positive advanced gastrointestinal tumor (GIST) and dermatofibrosarcoma protuberans. A wide spectrum of dermatologic toxicities has been associated with this agent, among which a maculopapular rash is the most common event. In addition, a variety of pigmentary abnormalities of the skin and mucosal surfaces have been reported. Hypopigmentation is a well-recognized adverse effect. In contrast, paradoxical hyperpigmentation has only rarely been documented. In this case report we describe imatinib-induced cutaneous hyperpigmentation and graying of hair occurring in the same patient with dermatofibrosarcoma protuberans treated with imatinib.
甲磺酸伊马替尼（STI 571；格列卫；瑞士巴塞尔诺华制药公司）是一种口服酪氨酸激酶抑制剂，靶向持续激活的BCR-ABL酪氨酸激酶，对血小板衍生生长因子（PDGF）受体α和β以及KIT也有额外的抑制作用。它彻底改变了费城染色体阳性慢性髓性白血病（CML）成人和儿童患者的治疗方式，并且还被美国食品药品监督管理局（FDA）批准用于治疗KIT阳性晚期胃肠道肿瘤（GIST）和隆突性皮肤纤维肉瘤。该药物与多种皮肤毒性相关，其中斑丘疹是最常见的情况。此外，还报告了皮肤和黏膜表面的多种色素沉着异常。色素减退是一种公认的不良反应。相比之下，矛盾性色素沉着仅有极少的记录。在本病例报告中，我们描述了一名接受伊马替尼治疗的隆突性皮肤纤维肉瘤患者出现伊马替尼诱导的皮肤色素沉着和头发变灰的情况。
